A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

This study has been completed.
Sponsor:
Information provided by:
Asahi Kasei Pharma Corporation
ClinicalTrials.gov Identifier:
NCT01285752
First received: January 27, 2011
Last updated: April 6, 2012
Last verified: April 2012

January 27, 2011
April 6, 2012
February 2011
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01285752 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
Not Provided

To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Rheumatoid Arthritis
  • Drug: AK106-001616
  • Drug: Active comparator
  • Experimental: 1
    Intervention: Drug: AK106-001616
  • Experimental: 2
    Intervention: Drug: AK106-001616
  • Active Comparator: 3
    Intervention: Drug: Active comparator
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
240
Not Provided
Not Provided

Inclusion Criteria:

  • Diagnosis of RA (class I to III)
  • Stable dose of methotrexate (at least 12 weeks)

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Abnormal screening laboratory test values considered to be clinically significant
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Poland,   Czech Republic,   Germany,   Hungary,   United Kingdom,   Slovakia,   Ukraine
 
NCT01285752
AK106 II-02
Not Provided
Not Provided
Asahi Kasei Pharma Corporation
Not Provided
Not Provided
Asahi Kasei Pharma Corporation
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP